Connect with us
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.


Robbins Arroyo LLP: Cancer Genetics, Inc. (CGIX) Sued by Shareholders in Recently Filed Class Action


Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Cancer Genetics, Inc. (NASDAQ: CGIX) have filed a class action complaint against the company’s officers and directors for alleged violations of the Securities Exchange Act of 1934 between March 23, 2017 and April 2, 2018. Cancer Genetics, develops, commercializes, and provides molecular and biomarker-based tests and services in the U.S., Europe, and Asia.

View this information on the law firm’s Shareholder Rights Blog:

Cancer Genetics Accused of Issuing Misleading Statements Regarding Its Controls Over Financial Reporting

According to the complaint, beginning on March 23, 2017 and continuing through the class period, Cancer Genetics reaffirmed in filings with the Securities and Exchange Commission that “our disclosure controls and procedures were effective.”

On April 2, 2018, after the market closed, Cancer Genetics revealed that its “disclosure controls and procedures were not effective at December 31, 2017 as a result of the material weaknesses in internal controls¦ [and] may not prevent or detect misstatements.”

On this news, Cancer Genetic’s shares fell $0.55, or over 33.3% per share on April 3, 2018, and have yet to recover.

Cancer Genetics Shareholders Have Legal Options

If you would like more information about your rights and potential remedies, contact attorney Leonid Kandinov at (800) 350-6003,, or via the shareholder information form on the firm’s website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

Robbins Arroyo LLP
Leonid Kandinov
525-3990 or Toll Free (800) 350-6003

Editorial & Advertiser disclosure

Call for Entries

Global Banking and Finance Review Awards Nominations 2022
2022 Awards now open. Click Here to Nominate

Newsletters with Secrets & Analysis. Subscribe Now


Global Banking & Finance Review® is a leading financial portal and Print Magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management. Copyright © 2010-2021 GBAF Publications Ltd - All Rights Reserved.